A Kanda1, K Noda, W Saito, S Ishida. 1. Laboratory of Ocular Cell Biology and Visual Science, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Abstract
AIMS/HYPOTHESIS: The renin-angiotensin system (RAS) potentially has a role in the development of end-organ damage, and tissue RAS activation has been suggested as a risk factor for diabetic retinopathy. We have recently shown significant involvement of (pro)renin receptor ([P]RR) in retinal inflammation in a rodent model of early diabetes. In this study we aim to elucidate the (P)RR-associated pathogenesis of fibrovascular proliferation, a late-stage angiogenic complication in human diabetic retinopathy. METHODS: Vitreous fluids from 23 eyes of patients with proliferative diabetic retinopathy (PDR) and 16 eyes of controls with non-diabetic, idiopathic macular diseases (macular hole and epiretinal membrane) were collected. Protein levels of soluble (P)RR were measured by ELISA, and immunofluorescence was performed to assess the localisation of (P)RR and related molecules in fibrovascular tissues from PDR eyes. RESULTS: (P)RR immunoreactivity was detected in neovascular endothelial cells, colocalised with prorenin, phosphorylated extracellular signal-regulated kinase (ERK) and vascular endothelial growth factor (VEGF). Prorenin application to human retinal microvascular endothelial cells significantly upregulated mRNA expression of VEGF, especially the VEGF165 isoform, which was abolished by (P)RR or ERK signalling blockade. Proteases known to cleave (P)RR, including furin, were positive in endothelial cells in fibrovascular tissues. Protein levels of soluble (P)RR in vitreous fluids were higher in PDR eyes than in non-diabetic control eyes, and correlated significantly with vitreous prorenin and VEGF levels and the vascular density of fibrovascular tissues. CONCLUSIONS/ INTERPRETATION: Our data using human samples provide the first evidence that (P)RR is associated with angiogenic activity in PDR.
AIMS/HYPOTHESIS: The renin-angiotensin system (RAS) potentially has a role in the development of end-organ damage, and tissue RAS activation has been suggested as a risk factor for diabetic retinopathy. We have recently shown significant involvement of (pro)renin receptor ([P]RR) in retinal inflammation in a rodent model of early diabetes. In this study we aim to elucidate the (P)RR-associated pathogenesis of fibrovascular proliferation, a late-stage angiogenic complication in humandiabetic retinopathy. METHODS: Vitreous fluids from 23 eyes of patients with proliferative diabetic retinopathy (PDR) and 16 eyes of controls with non-diabetic, idiopathic macular diseases (macular hole and epiretinal membrane) were collected. Protein levels of soluble (P)RR were measured by ELISA, and immunofluorescence was performed to assess the localisation of (P)RR and related molecules in fibrovascular tissues from PDR eyes. RESULTS: (P)RR immunoreactivity was detected in neovascular endothelial cells, colocalised with prorenin, phosphorylated extracellular signal-regulated kinase (ERK) and vascular endothelial growth factor (VEGF). Prorenin application to human retinal microvascular endothelial cells significantly upregulated mRNA expression of VEGF, especially the VEGF165 isoform, which was abolished by (P)RR or ERK signalling blockade. Proteases known to cleave (P)RR, including furin, were positive in endothelial cells in fibrovascular tissues. Protein levels of soluble (P)RR in vitreous fluids were higher in PDR eyes than in non-diabetic control eyes, and correlated significantly with vitreous prorenin and VEGF levels and the vascular density of fibrovascular tissues. CONCLUSIONS/ INTERPRETATION: Our data using human samples provide the first evidence that (P)RR is associated with angiogenic activity in PDR.
Authors: Erica L Fletcher; Joanna A Phipps; Michelle M Ward; Kirstan A Vessey; Jennifer L Wilkinson-Berka Journal: Prog Retin Eye Res Date: 2010-04-07 Impact factor: 21.198
Authors: N Chaturvedi; A K Sjolie; J M Stephenson; H Abrahamian; M Keipes; A Castellarin; Z Rogulja-Pepeonik; J H Fuller Journal: Lancet Date: 1998-01-03 Impact factor: 79.321
Authors: Jan H Schefe; Mario Menk; Jana Reinemund; Karin Effertz; Robin M Hobbs; Pier Paolo Pandolfi; Patricia Ruiz; Thomas Unger; Heiko Funke-Kaiser Journal: Circ Res Date: 2006-11-02 Impact factor: 17.367
Authors: A H Danser; M A van den Dorpel; J Deinum; F H Derkx; A A Franken; E Peperkamp; P T de Jong; M A Schalekamp Journal: J Clin Endocrinol Metab Date: 1989-01 Impact factor: 5.958
Authors: L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park Journal: N Engl J Med Date: 1994-12-01 Impact factor: 91.245
Authors: Sunil K Parapuram; Radu I Cojocaru; Jessica R Chang; Ritu Khanna; Matthew Brooks; Mohammad Othman; Sepideh Zareparsi; Naheed W Khan; Norimoto Gotoh; Tiziana Cogliati; Anand Swaroop Journal: PLoS One Date: 2010-11-08 Impact factor: 3.240
Authors: Rashidul Haque; P Michael Iuvone; Li He; Elizabeth H Hur; Kimberly Su Chung Choi; Daniel Park; Annie N Farrell; Ashley Ngo; Samantha Gokhale; Madiha Aseem; Bhavna Kumar Journal: J Recept Signal Transduct Res Date: 2017-08-25 Impact factor: 2.092